First Tracks Biotherapeutics, Inc.
Ownership
Ownership Structure
Who owns First Tracks Biotherapeutics, Inc. (TRAX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 73.2% of the shares are freely tradable; institutional investors hold 46.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 8.88 | 3,174,519 | +0.0 | 06/30/2026 |
| TCG Crossover Management, LLC | 8.10 | 2,895,304 | +0.0 | 06/30/2026 |
| Affinity Asset Advisors, LLC | 5.69 | 2,032,012 | +0.0 | 06/30/2026 |
| Trails Edge Capital Partners, LP | 4.24 | 1,514,000 | +0.0 | 06/30/2026 |
| Sanofi | 2.30 | 821,917 | +0.0 | 06/30/2026 |
| Adage Capital Partners Gp LLC | 2.04 | 729,000 | +0.0 | 06/30/2026 |
| Palo Alto Investors, LLC | 1.69 | 603,489 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.11 | 1,111,470 | +0.0 | 07/31/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.75 | 981,792 | -1.1 | 08/31/2026 |
| FIAM Small Cap Core CIT Cl B | 1.74 | 622,700 | +20.9 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Ware J. Anthony | Director | 15,660 | 613,872 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ware J. Anthony | Director | Sell | 39,265 | 44.78 | 1,758,145 |
| Sep 2, 2026 | Ware J. Anthony | Director | Other | 39,265 | 5.74 | 225,381 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.